Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema
Switching to faricimab in treatment resistant eyes led to improved anatomical response and extended treatment interval in a significant proportion of patients. Ongoing review of real-world data will inform longer-term outcomes of safety and effectiveness.
Authors
- Niamh Stone
- Handan Akıl (ORCID: https://orcid.org/0000-0002-7361-9379)
- Samantha Roshani De Silva (ORCID: https://orcid.org/0000-0002-4455-2814)
- Christine A. Kiire (ORCID: https://orcid.org/0000-0003-4116-0783)
- Grace A. Borchert (ORCID: https://orcid.org/0000-0002-1395-6875)
- Robert E. MacLaren (ORCID: https://orcid.org/0000-0002-3096-4682)
- Theodora Gkika
- Jasmina Cehajic‐Kapetanovic (ORCID: https://orcid.org/0000-0002-9956-6412)
- Kanmin Xue (ORCID: https://orcid.org/0000-0003-0065-9131)
- Peter Charbel Issa (ORCID: https://orcid.org/0000-0002-0351-6673)
- Susan M. Downes (ORCID: https://orcid.org/0000-0001-7373-2665)
- Manuel Fischer (ORCID: https://orcid.org/0000-0001-7459-1024)
Institutions
- Nuffield Orthopaedic Centre (GB)
- Oxford Health NHS Foundation Trust (GB)
- University of Oxford (GB)
- Technical University of Munich (DE)
Publication Details
- Journal
- Eye
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1038/s41433-024-03364-y
- Citations
- 36
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 19.39
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- University of Oxford
- Medical Research Council
- NIHR Oxford Biomedical Research Centre